New study links menopause hormone therapy to increased migraine burden: what Canadian patients should know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A meta-analysis of nearly 24,000 postmenopausal women, presented October 20, 2026, at The Menopause Society Annual Meeting in San Diego, found that hormone therapy (HT) was associated with more frequent migraine attacks and longer migraine episodes, though it did not worsen pain severity scores or increase monthly painkiller use. For Canadian women currently on HT or considering it, the finding adds a layer of nuance to an already complex decision, but it does not overturn the established evidence that HT is the most effective treatment for vasomotor symptoms such as hot flashes.

Migraines affect an estimated 10% to 29% of women during the menopause transition, a period when fluctuating and falling estrogen levels can make attacks more frequent and harder to predict. The study, a systematic review and meta-analysis pooling five separate studies, reported a mean migraine incidence of 18.94% across the pooled population. Lead author Dr. Flavia Fairbanks Ruano of the University of Miami Miller School of Medicine noted that further clinical trials are needed before the findings can guide treatment changes. The Menopause Society's medical director, Dr. Stephanie Faubion, was direct: "Hormone therapy remains the most effective treatment for bothersome vasomotor symptoms and can be used safely in many women with migraine."

What this means in Canada

Health Canada has approved several forms of systemic hormone therapy for menopausal symptom management, including oral estradiol (sold in Canada as Estrace), transdermal estradiol patches (Estradot, Climara), and combined estrogen-progestogen products. Health Canada has not issued specific guidance on HT use in women with migraine history, and as of this writing the Society of Obstetricians and Gynaecologists of Canada (SOGC) has not published a position statement specifically addressing the HT-migraine association identified in this meta-analysis.

Provincial drug coverage for HT varies. In Ontario, some HT formulations are listed on the Ontario Drug Benefit formulary for eligible patients, but coverage depends on the specific product and patient eligibility. In Quebec, the Régie de l'assurance maladie du Québec (RAMQ) covers select HT products under its public drug plan. British Columbia's PharmaCare and Alberta's Alberta Health Care Insurance Plan (AHCIP) each have their own formulary listings; patients should verify current coverage directly with their provincial plan or pharmacist, as formularies change.

Canadian women seeking HT through virtual care platforms, including Cleo (a Canadian women's-health platform), Felix, Maple, and Telus Health, can discuss migraine history with prescribing clinicians during their intake. Science & Humans (scienceandhumans.com), another Canadian platform offering hormone-related care, similarly conducts clinical intake that would capture migraine history. None of these platforms replace a neurologist or headache specialist for complex migraine management.

What changed

Prior to this meta-analysis, the clinical picture on HT and migraine was mixed. Individual studies had pointed in different directions, and the general clinical consensus, reflected in Menopause Society guidance, was that HT could be used in women with migraine, with transdermal routes often preferred because they produce steadier estrogen levels and avoid the peaks and troughs associated with oral dosing. Those peaks and troughs are thought to be a migraine trigger.

This new pooled analysis, covering five studies and nearly 24,000 women, is the largest synthesis to date on the question. Its finding of increased attack frequency and episode duration is statistically notable. But the absence of any difference in pain severity or analgesic use complicates the picture. More frequent migraines that are no more painful and require no more medication may represent a different clinical burden than the raw frequency number implies.

Dr. Faubion flagged a methodological concern that Canadian clinicians should weigh: women with migraine may be more likely to seek HT in the first place, because they are already engaged with the healthcare system for symptom management. If that is true, the association between HT use and higher migraine frequency could partly reflect who ends up in the HT group, not a direct pharmacological effect of the hormones.

What Canadian patients should know

If you have a history of migraine and are considering HT, or are already using it, this study is not a reason to stop without talking to your prescriber. The Menopause Society's position, which Canadian clinicians generally follow in the absence of SOGC-specific guidance, is that HT remains appropriate for many women with migraine.

A few practical points are worth raising with your doctor or nurse practitioner:

• Route of administration matters. Transdermal estradiol (patches, gels) produces more stable estrogen levels than oral tablets and is generally preferred for women with migraine, based on existing clinical reasoning. This meta-analysis did not find differences by route, but the authors note that further trials are needed to examine this specifically.
• Migraine with aura is a separate consideration. Women who have migraine with aura face a modestly elevated stroke risk, and combined estrogen-progestogen oral contraceptives are generally avoided in this group. The stroke-risk question with menopausal HT doses is different and should be discussed individually with a clinician.
• Keep a headache diary. If you start or change HT and notice a shift in migraine frequency or duration, documenting it gives your prescriber concrete data to work with.
• Provincial differences in specialist access are real. Neurologists and headache specialists have long wait times in many Canadian provinces. If migraine is a significant concern, ask your family doctor or gynaecologist for a referral early, rather than waiting for symptoms to worsen.

Limitations and open questions

The meta-analysis pooled only five studies, and the authors themselves call for further clinical trials. The pooled design means differences in how each study defined "migraine burden," measured frequency, or selected participants can introduce noise into the combined result.

The selection-bias concern raised by Dr. Faubion is not resolved by this analysis. A randomized controlled trial, where women with migraine history are assigned to HT or placebo, would be needed to separate a true pharmacological effect from a pre-existing difference between HT users and non-users. No such trial currently exists at scale.

Health Canada has not commented on this specific meta-analysis, and the SOGC has not issued updated guidance. Until more evidence accumulates, Canadian clinicians will likely continue applying individualized judgment, weighing each patient's vasomotor symptom burden, migraine history, cardiovascular risk, and quality-of-life priorities.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.